Devon J Shedlock Email & Phone Number

San Diego, California, United States

Report to CEO of Poseida Therapeutics, a NASDAQ-traded (PSTX) clinical-stage biopharmaceutical company that is therapeutics-focused and translating best-in-class gene therapy technologies into lifesaving cell therapies. Cell Therapy mission is to discover, innovate and develop cell-based therapies for the treatment of cancer, autoimmune, and infectious diseases.Poseida is dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and… Show more Report to CEO of Poseida Therapeutics, a NASDAQ-traded (PSTX) clinical-stage biopharmaceutical company that is therapeutics-focused and translating best-in-class gene therapy technologies into lifesaving cell therapies. Cell Therapy mission is to discover, innovate and develop cell-based therapies for the treatment of cancer, autoimmune, and infectious diseases.Poseida is dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac® DNA Modification System, Cas-CLOVER™ Site-Specific Gene Editing System and biodegradable nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics Show less

Greater San Diego Area

Responsible for the four core functional preclinical development groups: Immuno-Oncology, Gene Therapy, Nanotechnology and Genetic Engineering. R&D's mission was to discover, innovate and develop cell- and gene-based therapies, nanoparticle- and AAV-based delivery technologies, and optimize our proprietary gene engineering platform technologies, for the treatment of cancer, autoimmune, infectious and genetic diseases.Team developed Poseida's first allogeneic CAR-T immunotherapy from… Show more Responsible for the four core functional preclinical development groups: Immuno-Oncology, Gene Therapy, Nanotechnology and Genetic Engineering. R&D's mission was to discover, innovate and develop cell- and gene-based therapies, nanoparticle- and AAV-based delivery technologies, and optimize our proprietary gene engineering platform technologies, for the treatment of cancer, autoimmune, infectious and genetic diseases.Team developed Poseida's first allogeneic CAR-T immunotherapy from concept to clinic; P-BMCA-ALLO1 is a fully-allogeneic BCMA-specific CAR-T memory stem cell immunotherapy for the treatment of multiple myeloma. Show less

San Diego, California

Team advanced Poseida's first CAR-T immunotherapy against a solid tumor, from concept to clinic; P-PSMA-101 is a PSMA-specific CAR-T memory stem cell immunotherapy for the treatment of castrate-resistant prostate cancer.

San Diego, California

Team developed Poseida's first CAR-T immunotherapy from concept to clinic; P-BMCA-101 is a BCMA-specific CAR-T memory stem cell immunotherapy for the treatment of multiple myeloma.

San Diego, Ca

As Poseida's first employee, assembled and led a team advancing immuno-oncology efforts in the development of chimeric antigen receptor (CAR)-T cellular therapies using the nonviral piggyBac® DNA Delivery System• Assembled and led a highly effective and innovative team of scientists• Developed non-viral delivery platforms and advanced Gene Editing approaches• Designed traditional and alternative non-scFv (Centyrin) CARs, safety switch technologies, immune modulation and… Show more As Poseida's first employee, assembled and led a team advancing immuno-oncology efforts in the development of chimeric antigen receptor (CAR)-T cellular therapies using the nonviral piggyBac® DNA Delivery System• Assembled and led a highly effective and innovative team of scientists• Developed non-viral delivery platforms and advanced Gene Editing approaches• Designed traditional and alternative non-scFv (Centyrin) CARs, safety switch technologies, immune modulation and anti-suppression/exhaustion strategies• Drove early manufacturing process development of autologous and allogeneic CAR-T cell products Show less

Philadelphia, Pa

Department of Pathology & Laboratory Medicine

Philadelphia, Pa

The T Cell Engineering Lab is a member of The Translational Research Program, as directed by Dr. Carl June, at the Abramson Family Cancer Research Institute, and promotes patient-based testing of novel molecular and cellular therapies developed at UPenn, as well as a part of the UPenn-Novartis broad-based R&D alliance, which advances novel T-cell immunotherapies to treat cancer.• Developed products, including RNA CAR T cells and novel T cell receptors (TCR)s, against cancer and infectious… Show more The T Cell Engineering Lab is a member of The Translational Research Program, as directed by Dr. Carl June, at the Abramson Family Cancer Research Institute, and promotes patient-based testing of novel molecular and cellular therapies developed at UPenn, as well as a part of the UPenn-Novartis broad-based R&D alliance, which advances novel T-cell immunotherapies to treat cancer.• Developed products, including RNA CAR T cells and novel T cell receptors (TCR)s, against cancer and infectious disease for translation into the clinic• Directed collaboration and coordination with the major Penn School of Medicine research labs for integrating resources to establish a platform for TCEL R&D work• Assisted in lab operation, management, budget, strategic and programmatic planning Show less

Philadelphia, Pa

Led a team in the development of vaccine immunogens for numerous pathogens from the preclinic and later to clinical trials. Established models for evaluation of vaccine immunogenicity and efficacy, molecular adjuvants, genetic optimization strategies, and advanced delivery technologies. Generated antibody reagents and constructed polychromatic flow cytometry (PFC) panels for mice, monkeys, and humans. Developed novel immunoassays for cellular activation and lytic potential, non-CFSE-based… Show more Led a team in the development of vaccine immunogens for numerous pathogens from the preclinic and later to clinical trials. Established models for evaluation of vaccine immunogenicity and efficacy, molecular adjuvants, genetic optimization strategies, and advanced delivery technologies. Generated antibody reagents and constructed polychromatic flow cytometry (PFC) panels for mice, monkeys, and humans. Developed novel immunoassays for cellular activation and lytic potential, non-CFSE-based proliferative assays, and characterization of vaccine-induced immunity Show less

Philadelphia, Pennsylvania, United States

Evaluated therapeutic DNA vaccination of macaques during chronic SIV infection and developed novel assays for assessment of antigen-specific proliferative responses in vaccinated macaques and humans

Bethesda, Md

Characterized mechanisms of neutralization by highly-reactive, human antibodies against Ebola and developed flow cytometric assays for the evaluation of virus-specific T cell responses in vaccinated macaques

Philadelphia, Pa

PhD, Cell & Molecular Biology, Microbiology and Virology subgroup (focus on host-pathogen interaction)Demonstrated CD4+ T cells disposable for primary CD8+ T cell responses, but critical for the generation of functional CD8+ T cell memory

Collegeville, Pa

"High throughput screening and identification of genes highly regulated in human atherosclerosis using DNA microarray". Awarded by Biology Department for most promising student researcher in the Biological Sciences

Collegeville, Pa

BS, Biology with Honors, cum laudeDissertation: Immunology & "Analysis of halophage HF2 binding to the extremely halophilic archaeon Halorubrum coriense"

Phd, Cell And Molecular Biology; Immunology And Microbiology

PhD Thesis Title: "Role of CD4 T cell help in CD8 T cell responses to infection"

Bs, With Honors, Biology

"Phage HF2 binding to the extremely halophilic archaeon Halorubrum coriense”